logo
What is bronchitis, and is it contagious?

What is bronchitis, and is it contagious?

USA Today12-03-2025

What is bronchitis, and is it contagious?
Show Caption
Hide Caption
Spring allergy survival guide: Expert tips to breathe easier
Cleveland Clinic's Dr. Sandra Hong gives some tips on how to beat spring allergies.
About one in 20 people experience bronchitis every year, despite it being a respiratory infection no one wants. Its most common symptoms include wheezing, chest tightness, low fever, fatigue, shortness of breath "and an irritating cough that may last anywhere from days to a couple of weeks," says Dr. Jason Nagata, a pediatrician at UCSF Benioff Children's Hospital in San Francisco.
Though such symptoms are uncomfortable for everyone, they can be more serious in babies, young children, the elderly and the immunocompromised. Bronchitis can even be deadly as some 350 people in the U.S. die from the illness every year, per the Centers for Disease Control and Prevention.
Here's what causes bronchitis, how the illness usually spreads and how you can treat symptoms if it affects you or a loved one.
What causes bronchitis?
Bronchitis is a respiratory illness that occurs when the airways leading into your lungs get irritated, Nagata explains, which leads to the swelling and mucus buildup that causes difficulty breathing.
Different factors cause this lung irritation to occur, depending on the type of bronchitis one is dealing with. Individuals suffering from what's called acute or viral bronchitis get the illness from viruses such as RSV, coronavirus, the common cold (rhinovirus) and influenza.
The other main form of bronchitis is called chronic bronchitis. It's usually caused by long-term exposure to environmental irritants such as cigarette smoke, chemicals, allergens, air pollution and dust, explains Dr. Kunal Bakshi, a primary care physician at Rush University Medical Center in Chicago.
Bronchitis can also be caused by bacteria like streptococcus pneumoniae and medical conditions such as GERD or COPD.
Is bronchitis contagious?
Understanding the different types of bronchitis can also be helpful in understanding when the illness is and isn't contagious. Chronic bronchitis caused by environmental irritants, for instance, is not contagious. But acute or viral bronchitis is. "Viral bronchitis can be spread from person to person by inhaling droplets produced when an infected person coughs, sneezes or talks," says Nagata.
The viruses that cause bronchitis can also be spread by touching an object or surface that has the virus on it, then touching your mouth, nose or eyes.
Getting vaccinated against viruses like the coronavirus and influenza can help provide protection against viral bronchitis—as can washing your hands frequently, avoiding close contact with people who are sick and keeping your immune system healthy with a well-balanced diet and plenty of exercise.
How to treat bronchitis
In healthy people, bronchitis usually goes away on its own within a week or two with "plenty of rest and drinking lots of water," says Nagata. In the meantime, symptoms can be treated with over-the-counter drugs such as cough suppressants, nasal sprays and pain medicines like as ibuprofen and acetaminophen. "Using a humidifier may also help alleviate symptoms," says Nagata.
Such at-home treatments are all that is usually required, "but you should see a healthcare provider if your cough lasts more than two to three weeks, worsens or causes difficulty breathing," advises Nagata.
In such cases, a doctor can determine if there's another underlying issue at play and recommend additional medical interventions. These may include an oxygen supply to make breathing easier and specific medications. Antibiotics are rarely recommended to treat acute bronchitis, however, "as the main cause of the infection is viral in nature," says Bakshi, and antibiotics are only designed to target and kill bacteria, not viruses. But he adds that antiviral medicines are sometimes recommended to treat specific bronchitis-causing viruses such as COVID-19 or the flu.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Yahoo

time4 hours ago

  • Yahoo

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Immunizations begin in early fall and these advance shipments provide confidence for healthcare providers to support their efforts. Demand has continued to increase since the launch of Beyfortus, the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy through a typical RSV season and an unparalleled body of real-world evidence. Sanofi, in collaboration with its partner AstraZeneca, has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Current supply for the upcoming season already matches the total doses distributed last year and production continues. Last season in the US, enough doses were produced to cover every infant — a benchmark that reflects both Sanofi's and AstraZeneca's global commitment to ensuring timely access for all infants. Executive Vice President, Vaccines'Our third year of providing RSV protection marks a transformative era in infant health. Backed by more than 40 real-world studies involving 250,000 immunized infants, Beyfortus has consistently proven itself as an effective RSV immunization. To meet growing demand since launch, we have meticulously primed our global distribution network to ensure Beyfortus will continue to deliver significant public health impact and offer high, sustained efficacy for infants regardless of underlying health conditions or the timing of when they are born.' Beyfortus duration of protection extended through six months in the EUThis year's EU shipments are marked by an important change to the Beyfortus EU label extending the duration of protection through six months, so Beyfortus can continue to offer season-long protection for all infants, including older babies immunized just before the RSV season begins. More than six million babies have been immunized worldwide and millions more will be immunized this season in more than 40 countries to help protect them from the potentially devastating impact of RSV disease. All infants are at risk from RSVRSV is a highly contagious virus infecting two out of three infants in their first year of life and nearly all children by their second birthday. RSV is the main cause of lower respiratory tract disease and a leading cause of hospitalization in all infants worldwide, with most hospitalizations occurring in healthy infants born at term. With an extended half-life of 71 days, Beyfortus stands apart as the longest-acting monoclonal antibody for the prevention of RSV lower respiratory tract disease in infants, and the only RSV immunization designed to protect all infants born before or during the RSV season, at term or preterm, healthy or with underlying conditions. Administration can be timed to coincide with the RSV season and provided directly to newborns and infants as a single dose. Beyfortus offers rapid protection without requiring activation of the immune system. Beyfortus is also designed to protect children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus was approved and granted special designations to expedite development across major geographies including the US, the EU, Japan and China. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Doctors recommend MMR vaccine amid measles outbreaks
Doctors recommend MMR vaccine amid measles outbreaks

Yahoo

time5 hours ago

  • Yahoo

Doctors recommend MMR vaccine amid measles outbreaks

(WKBN) — The Centers for Disease Control recently issued a travel warning for Americans as measles cases continue to rise around the world. Doctors say kids who are not vaccinated are at higher risk for serious problems from measles. The MMR vaccine helps protect against measles, mumps and rubella and has been used for many years. Dr. Camille Sabella with the Cleveland Clinic is a pediatric infectious disease specialist. She says the first dose of the MMR vaccine is given when a child is about 12 months old, and the second dose is given between 4 and 6 years old. Sabella says measles is a very contagious illness that spreads through coughing and sneezing. 'Most cases of measles in this country, and most of the outbreaks that we've had, began with someone who was not fully vaccinated against measles traveling internationally where measles is incredibly common,' Sabella said. Sabella says if you've recently traveled and have a rash, high fever, cough, runny nose or red, watery eyes, you should see a doctor right away but make sure you call before you go because you could be contagious. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Meth makes comeback in Minnesota in more dangerous and record ways
Meth makes comeback in Minnesota in more dangerous and record ways

Miami Herald

time12 hours ago

  • Miami Herald

Meth makes comeback in Minnesota in more dangerous and record ways

A subtle shift was happening among clients at the north Minneapolis community drop-in center. For years, people seeking substance abuse services at Anything Helps reported using just one drug of choice. Recently, staff noticed more and more users had expanded their appetite, preferring a combination of drugs at once versus 'picking a lane.' The polysubstance abuse among their regulars soon evolved almost exclusively to one pairing of drugs in the majority of their clients: fentanyl and methamphetamine. 'That's pretty new,' according to Brian Warden, the nonprofit's harm reduction director. 'That's something we traditionally see in cities like Denver, San Francisco or Seattle. That's not something we've really seen here.' To Warden, the change in the clientele's drug use pattern could stem from a number of reasons, including a correlation with a rise in homelessness in Minneapolis. But undoubtedly, he said, the phenomenon can be explained in part by the recent surge of methamphetamine in Minnesota. As the deadly fentanyl crisis demanded the state's attention post-pandemic, another was building with methamphetamine. The stimulant, long supreme in the underbelly of Minnesota's drug scene, is flooding the state - with a more dangerous dosage than meth of the past. 'The numbers are just a ridiculous amount of meth ... it just hasn't gotten enough publicity,' said Rafael Mattei, acting special agent in charge of the U.S. Drug Enforcement Administration's division over Minnesota. The meth surge in Minnesota came just as the street fentanyl crisis showed signs of easing. U.S. opioid overdose deaths plummeted 41% in 2024, according to the Centers for Disease Control and Prevention, and fatal overdoses of all kinds fell 27%. In Minnesota, preliminary data from the Minnesota Department of Health showed an 8% drop in overall overdose deaths from 2022 to 2023. But meth 'has never gone away,' Mattei said. No longer homemade in makeshift labs, meth is being churned out of Mexican super labs by cartels that cashed in on the lack of supply and cheaper production costs. And its price has plummeted, becoming a more lucrative option for dealers. Ken Sass, statewide drug and gang coordinator for the Minnesota Department of Public Safety, recalled a pound of meth costing $3,000 to $5,000 around 15 years ago, during his tenure as a federal drug agent. Now, he estimates, the price has fallen below $1,000. The drug makes its way to Minnesota most often by snaking up the Interstate 35 corridor to be sold in droves or continue into neighboring states. Last year, federal officials announced they had busted 'one of the largest and most prolific drug organizations' in Minnesota's history following the arrest of a Twin Cities man accused of helping push a historic amount of meth and other substances from Mexico. Federal prosecutors allege Clinton Ward made ties with two of Mexico's most notorious drug cartels and funneled the substance across the border via shipping containers, private vehicles and semitrailers before breaking the drug down into smaller quantities, then delivering it to Minnesota. The U.S. Attorney's Office charged Ward under the rare 'kingpin' statute, along with 14 others in the conspiracy case that led to the seizure of 1,600 pounds of methamphetamine, 4 kilograms of cocaine, 2 kilograms of fentanyl and 30,000 counterfeit fentanyl pills. Federal officials described the bust as a success for having disrupted a major pipeline of illegal drugs in Minnesota. Yet methamphetamine is continuing to pour into Minnesota with no sign of slowing down, data from the DEA indicates. Last year, the amount of methamphetamine seized by federal agents in Minnesota increased 142%, totaling 2,080 pounds, compared with the roughly 860 pounds of meth seized in 2023. The numbers do not include drugs seized by state, local or tribal law enforcement. Federal drug agents are on track to outpace the amount of meth seized last year. They've seen a 25% increase in the amount of meth seized from January to April 2025, compared with the same time last year. More readily available meth, Sass said, 'leads to more addiction and probably a broadening market as well.' And although meth may not be as lethal as fentanyl, the drug today poses its own dangers. The meth from Mexican super labs holds higher potency, resulting in a more dangerous and addictive concoction than the meth sold in the 1990s and early 2000s. After federal legislation in 2005 cracked down on the commercial sale of products containing precursor chemicals to make meth, such as pseudoephedrine in the decongestant Sudafed, cartels pursued the chemicals overseas and became bulk buyers. The product is then cut with other hazardous materials to bring maximum profit. Users deep in the throes of meth addiction can stay awake for days, leading to paranoia and hallucinations. A hallmark sign of meth addiction is wounds on a user's skin caused by incessant scratching. People who experience withdrawals may resort to theft, robbery or other crimes to obtain money for another hit. The elevated potency can only worsen symptoms, which carry ripple effects into communities. 'Their health, their mental health, their relationships, medical conditions that arise from addiction and all the personal problems that would come from [addiction] ... they relay that to the relationships with their family,' Sass said. In some cases, law enforcement and treatment providers are seeing fentanyl added to methamphetamine. Though the risk of dying from a meth overdose is much lower than that of fentanyl, which has a deadly dose that can fit on the tip of a pencil, the drug takes its toll 'little by little.' 'There is no accident here,' Warden said, saying of the adulteration of fentanyl with meth, 'I've never seen anything like that before.' Mattei likened the difference between the meth on the streets today compared with meth of the past as that of whiskey versus beer. 'They were making beer first,' Mattei said. 'Now the meth that's out there is kind of like higher-proof alcohol. So you need less to feel.' Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store